Clinical outcomes after switching from sulfamethoxazole-trimethoprim to atovaquone due to intolerance in patients with non-HIV Pneumocystis pneumonia: a single-center retrospective study
Our data suggest that switching from SMX/TMP to Atov may not be associated with worse survival. Long-term administration of SMX/TMP is often challenging due to its side effects, and in this study, more than 30% of patients were unable to tolerate its therapeutic dose. Our findings support the role of Atov as a viable second-line treatment for PCP in immunocompromised patients, such as those with non-HIV PCP.
Authors
- Mika Higashi
- Susumu Kaneshige
- Takuya Yamashina (ORCID: https://orcid.org/0000-0002-1044-265X)
- Keisuke Sato (ORCID: https://orcid.org/0000-0002-2579-6581)
- Atsushi Togawa (ORCID: https://orcid.org/0000-0001-6419-8480)
- Masanobu Uchiyama (ORCID: https://orcid.org/0000-0001-6385-5944)
- Takafumi Nakano (ORCID: https://orcid.org/0000-0001-5667-1979)
- Yukiomi Eguchi
- Hidetoshi Kamimura
- Yukino Shirakawa
- Tadahiro Ikeuchi
- Yuka Takahashi
- Koichi Matsuo
Institutions
- Fukuoka University (JP)
- Fukuoka University Hospital (JP)
Publication Details
- Journal
- Journal of Pharmaceutical Health Care and Sciences
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1186/s40780-025-00516-4
- Primary Topic
- Pneumocystis jirovecii pneumonia detection and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00